Doctors perform transurethral ultrasound ablation (TULSA) procedures using the TULSA-PRO system. This treats people with prostate disease, including prostate cancer or an enlarged prostate. New ...
TORONTO, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, ...
TORONTO, June 10, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...
Company’s year-end TULSA-PRO installed base stood at 78 systems; qualified sales pipeline grew to 97 new systems ...
TORONTO, June 04, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...
Hosted on MSN
Profound Medical targets 70–75% revenue growth in 2025 as TULSA-AI and CAPTAIN trial progress fuel confidence
CEO Arun Swarup Menawat summarized that "our sales team has been stabilized. That, combined with our large and growing TULSA-PRO pipeline, continues to drive our confidence in our ability to deliver ...
Profound Medical (PROF) announced that The Johns Hopkins Hospital has treated its first non-clinical-trial prostate cancer patient using the ...
Mount Sinai advances prostate care with AI-powered therapy designed to preserve continence and sexual function ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results